Rabenosyn-5 suppresses non-small cell lung cancer metastasis via inhibiting CDC42 activity
Cancer Gene Therapy – Rabenosyn-5 suppresses non-small cell lung cancer metastasis via inhibiting CDC42 activity
Related Articles
Melanoma Among Adult Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study
PURPOSEMelanoma as a subsequent malignant neoplasm has been described among childhood cancer survivors; however, the risk factors and long-term survival are not well understood.METHODSWe assessed…
Summer Internship Program (SIP)
Official websites use .gov A.gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock () or…
Selecting Checkpoint Inhibitor–Based Regimens in Clear Cell RCC Requires Several Considerations
Yousef Zakharia, MD, discusses the evolving use of checkpoint inhibitors and emerging triplet regimens in clear cell renal cell carcinoma.
Novel Immunotherapy Trials May Drive Progress in Kidney Cancer Field
Various kidney cancer trials have combined agents such as A2a receptor inhibitors with immunotherapy backbones to potentially improve treatment outcomes.
Eight weeks of aerobic exercise, but not four, improves insulin sensitivity and cardiovascular performance in young women
Scientific Reports – Eight weeks of aerobic exercise, but not four, improves insulin sensitivity and cardiovascular performance in young women
Prospective validation of ORACLE, a clonal expression biomarker associated with survival of patients with lung adenocarcinoma
Nature Cancer – Swanton and colleagues present a clonal expression signature, ORACLE, which, in combination with clinicopathological and molecular risk factors, can predict survival of…
Hema Now: Episode 8: What’s Next in Lymphoma Diagnosis and Treatment?
Uncover the future of lymphoma care with Marc Hoffman, Professor, Hematologic Malignancies at the University of Kansas Medical Center.
OncLive’s December Roundup of Key FDA Approvals in Oncology
Here is your snapshot of all therapeutic options greenlit by the FDA in December 2024 spanning tumor types.
The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!